Compare ResMed Inc. (RMD) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Tencent Music Entertainment Group - ADR — how do they compare? ResMed Inc. trades at $197.45 (market cap $28.81B), while Tencent Music Entertainment Group - ADR trades at $9.16 (market cap $15.08B). The key difference: ResMed Inc. is the larger of the two by market cap, and Tencent Music Entertainment Group - ADR pays the higher dividend (2.62%). Which is the better fit depends on your goals.
| RMD | TME | |
|---|---|---|
Market Cap | $28.81B | $15.08B |
Sector | Health | Media |
52-Week High | $293.73 | $26.36 |
52-Week Low | $182.82 | $8.16 |
Enterprise Value | $27.99B | $11.85B |
Dividend Yield | 1.21% | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
TME trades at $8.94, down 1.97% for the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong 2025 revenue of $32.90B and net income of $11.06B, with a net income margin of 26.48%. Recent news highlights strategic moves like the Ximalaya acquisition and a partnership with Coca-Cola for the 2026 FIFA World Cup anthem.
The outlook is mixed; analyst consensus is a 'Hold' with a $14.00 price target, implying significant upside. Key opportunities include premium membership growth and ecosystem integration, while risks involve competition, user churn, and AI-related copyright issues. Cash flow trends show a projected recovery in 2026 after a negative 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
